Rani Therapeutics Holdings, Inc. (RANI) Insider Trading Activity

NASDAQ$0.5782+0.02 (3.60%)
Market Cap
$36.3M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
323 of 849
Rank in Industry
183 of 491

RANI Insider Trading Activity

RANI Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$50,033
2
67
Sells
$301
1
33

Related Transactions

Imran TalatChief Executive Officer
1
$25,193
0
$0
$25,193
IMRAN MIR A
1
$24,840
0
$0
$24,840
Javadi AlirezaChief Technical Officer
0
$0
1
$301
$-301

About Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of …

Insider Activity of Rani Therapeutics Holdings, Inc.

Over the last 12 months, insiders at Rani Therapeutics Holdings, Inc. have bought $50,033 and sold $301 worth of Rani Therapeutics Holdings, Inc. stock.

On average, over the past 5 years, insiders at Rani Therapeutics Holdings, Inc. have bought $2.95M and sold $9.33M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Imran Talat (Chief Executive Officer) — $25,193. IMRAN MIR A () — $24,840.

The last purchase of 36,000 shares for transaction amount of $24,840 was made by IMRAN MIR A () on 2026‑07‑21.

List of Insider Buy and Sell Transactions, Rani Therapeutics Holdings, Inc.

2026-07-21PurchaseIMRAN MIR A
36,000
0.055%
$0.69
$24,840
+15.55%
2026-07-17PurchaseImran TalatChief Executive Officer
35,000
0.0553%
$0.72
$25,193
+14.30%
2026-03-27SaleJavadi AlirezaChief Technical Officer
386
0.0005%
$0.78
$301
-0.02%
2025-10-23PurchaseIMRAN MIR A
2.08M
0.8362%
$0.60
$1.26M
-55.02%
2025-10-21SaleSouth Cone Investments Limited Partnership10 percent owner
4M
5.3233%
$2.77
$11.07M
-66.74%
2025-10-20SaleSouth Cone Investments Limited Partnership10 percent owner
1.92M
2.8236%
$2.41
$4.64M
-57.78%
2024-12-27SaleImran TalatChief Executive Officer
8,014
0.0137%
$1.41
$11,300
-21.13%
2024-12-13PurchaseMcKinley KateChief Business Officer
17,960
0.0313%
$1.67
$29,993
-32.53%
2024-12-09PurchaseImran TalatChief Executive Officer
10,296
0.018%
$1.94
$19,974
-41.71%
2024-10-15SaleSouth Cone Investments Limited Partnership10 percent owner
3.83M
8.9999%
$2.65
$10.14M
-46.70%
2023-12-06PurchaseImran TalatChief Executive Officer
10,000
0.0173%
$2.27
$22,700
+30.75%
2023-12-04PurchaseImran TalatChief Executive Officer
5,000
0.0101%
$2.57
$12,850
+30.24%
2023-11-29PurchaseImran TalatChief Executive Officer
20,000
0.0409%
$2.05
$41,000
+68.97%
2023-11-24SaleQuiroga Cortes Isidoro Alfonso10 percent owner
5.27M
10.2552%
$2.01
$10.58M
+64.18%
2023-11-24PurchaseSouth Cone Investments Limited Partnership10 percent owner
5.27M
10.2552%
$2.01
$10.58M
+64.18%
2023-11-17PurchaseBUTEL JEAN LUCdirector
50,500
0.0962%
$2.03
$102,495
+64.43%
2023-11-16PurchaseNanavaty Maulikdirector
500
0.0009%
$1.98
$990
+66.67%
2023-11-07PurchaseImran TalatChief Executive Officer
5,000
0.0095%
$2.00
$9,975
+66.41%
2023-05-12PurchaseSouth Cone Investments Limited Partnership10 percent owner
2,645
0.0104%
$3.98
$10,529
-10.57%
2023-05-11PurchaseSouth Cone Investments Limited Partnership10 percent owner
2,610
0.0102%
$3.87
$10,096
-8.16%
Total: 90
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
IMRAN MIR A
2119334
3.2445%
$1.18M21
<0.0001%
Imran TalatChief Executive Officer
469736
0.7191%
$261,079.2761
+30.93%
Quiroga Moreno Isidoro10 percent owner
11731654
17.9603%
$6.52M20
+50.37%
South Cone Investments Limited Partnership10 percent owner
2379194
3.6424%
$1.32M643
<0.0001%
BUTEL JEAN LUCdirector
50500
0.0773%
$28,067.9010
+64.43%
McKinley KateChief Business Officer
17960
0.0275%
$9,982.1710
<0.0001%
Quiroga Cortes Isidoro Alfonso10 percent owner
8400
0.0129%
$4,668.7251
<0.0001%
Nanavaty Maulikdirector
500
0.0008%
$277.9010
+66.67%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$2,542,362
111
11.81%
$36.83M
Rani Therapeutics Holdings, Inc.
(RANI)
$156,891,025
80
-24.91%
$36.3M
$84,911,583
59
17.82%
$37.44M
$693,326
47
-16.24%
$40.24M
$6,204,522
45
1.91%
$36.5M

RANI Institutional Investors: Active Positions

Increased Positions51+164.52%42M+1,090.09%
Decreased Positions9-29.03%728,756-19.02%
New Positions36New36MNew
Sold Out Positions9Sold Out728,756Sold Out
Total Postitions73+135.48%45M+1,071.07%

RANI Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$1,203.000.9%884,609+84,930+10.62%2025-09-30
Nan Fung Group Holdings Ltd$671.000.5%493,58400%2025-09-30
Citadel Advisors Llc$615.000.46%452,542+315,193+229.48%2025-09-30
United Services Automobile Association$412.000.31%302,74300%2025-09-30
Geode Capital Management, Llc$404.000.3%296,910+106,353+55.81%2025-09-30
Kestra Private Wealth Services, Llc$308.000.23%226,142+70,002+44.83%2025-09-30
Cwa Asset Management Group, Llc$204.000.15%150,000+66,667+80%2025-09-30
Blackrock, Inc.$164.000.12%120,232+1,580+1.33%2025-09-30
Hrt Financial Lp$154.000.12%113,206+113,206New2025-09-30
Northern Trust Corp$132.000.1%97,005-5,906-5.74%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.